158 results on '"Dziadziuszko, R."'
Search Results
2. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
3. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
4. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
5. 44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
6. Efficacité intracrânienne du sotorasib versus docétaxel dans le cancer bronchique non à petites cellules (CBNPC) métastatique muté KRAS G12C données utiles à la pratique issues d’un essai randomisé contrôlé
7. OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
8. OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
9. EP08.02-27 Trimodality Treatment of Superior Sulcus non-Small Cell Lung Cancer. An Institutional Series of 47 Consecutive Patients.
10. EP11.03-09 Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study
11. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
12. PO-1324 Body composition as a predictor of an in-field recurrence in stage III NSCLC patients
13. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
14. OC-0611 Lungtech EORTC 22113-08113 prospective multicenter trial: SBRT for central lung tumors.
15. 10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
16. 46O Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies
17. P4.11D.12 Phase 3 Trial of OSE2101 Versus Docetaxel in Patients with Non-Small Cell Lung Cancer & Secondary Resistance to Immunotherapy.
18. OA14.06 Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC.
19. 1397TiP Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
20. 624P Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study.
21. Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
22. LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
23. MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
24. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
25. 1024P Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
26. EP.11A.24 Clinical Prognostic Index for Immunochemiotherapy in Lung Cancer (CLIPI-LC)- A Prognostic Score for Advanced Non-Small-Cell Lung Cancer
27. OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
28. LBA51 Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial
29. LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
30. 1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
31. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
32. 941TiP A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
33. 616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors
34. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
35. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
36. Loss of STING expression is prognostic in non-small cell lung cancer.
37. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
38. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
39. Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
40. 142P Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
41. SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation
42. LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
43. LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
44. 1394P Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
45. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
46. 672P Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
47. 663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
48. 67 (PB057) - Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
49. LBA1 Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA.
50. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.